• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Improving outcomes in advanced malignant melanoma: update on systemic therapy.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Danson, Sarah
    Lorigan, Paul C
    Affiliation
    Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. sdanson@fsmail.net
    Issue Date
    2005
    
    Metadata
    Show full item record
    Abstract
    Malignant melanoma continues to increase in incidence throughout the developed world. Surgery remains the cornerstone of curative treatment and the use of adjuvant systemic therapy has provoked much debate. Metastatic disease is incurable in most patients. While combination chemotherapy or biochemotherapy may be considered in certain circumstances, it is now clear that single-agent chemotherapy remains the mainstay of treatment for the majority of patients.A number of new agents and novel approaches are under evaluation and show promise. The pro-apoptotic agent oblimersen has shown improved progression-free survival and response rate, although not overall survival, when combined with dacarbazine compared with dacarbazine alone. The BRaf inhibitor sorafenib (BAY 43-9006) has produced encouraging results when administered with chemotherapy and is now being assessed in randomised studies. Thalidomide in combination with chemotherapy is well tolerated and shows a trend towards increased clinical efficacy compared with chemotherapy alone. Other anti-angiogenic drugs, such as bevacizumab, are being investigated in trials. Results with tumour vaccines have been mixed and several large trials are ongoing.This paper discusses recent pivotal studies and promising new agents in systemic therapy for advanced malignant melanoma.
    Citation
    Improving outcomes in advanced malignant melanoma: update on systemic therapy. 2005, 65 (6):733-43 Drugs
    Journal
    Drugs
    URI
    http://hdl.handle.net/10541/75835
    PubMed ID
    15819587
    Type
    Article
    Language
    en
    ISSN
    0012-6667
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    • Issue date: 2007
    • Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
    • Authors: Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG, Oblimersen Melanoma Study Group
    • Issue date: 2006 Oct 10
    • Interleukin-2 for the treatment of melanoma.
    • Authors: Tarhini AA, Agarwala SS
    • Issue date: 2005 Dec
    • Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    • Authors: Flaherty LE
    • Issue date: 2000 Feb
    • Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
    • Authors: Egberts F, Kahler KC, Livingstone E, Hauschild A
    • Issue date: 2008 Jul
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.